Foundation19 Posted - 7 hours ago

$GRAL this is a long game and the runway with no new fund raise is 2027... so i will wait it out. i saw the GRAIL press release on doing late stage cancer detection with $AZN and Daichi Sankyo. No one is giving $GRAL credit for non MCED where they can do confirmatory tests and not just MCED. look at $GH market cap for comparison. https://grail.com/press-releases/grail-announces-first-patient-tested-with-blood-based-assay-in-global-phase-3-adjuvant-lung-cancer-study/

miggy99 Posted - 12 hours ago

$AZN Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick https://finance.yahoo.com/news/growth-investor-1-stock-could-144511304.html (shared via bit.ly/mystocksapp)

CharlesEscobar Posted - 20 hours ago

$AZN OK. Going Long common with calls now. Oversold. China ain't going away.

CantNameThatTune Posted - 21 hours ago

$RANI Careful. Company might just announce licensing of RANI pill in a $100 million agreement with $AZN

GreenEnergy2022 Posted - 21 hours ago

$ALT Will rally today off $NVO data. Best in class data, also on lean mass preservation and MASH data. phs3, 550mcap. I bet this company will be bought out in 2025. Maybe $PFE $LLY $AZN

CharlesEscobar Posted - 23 hours ago

$AZN These puts have been glorious. Even better than the $SAVA Puts.

miggy99 Posted - 23 hours ago

$AZN remains a Buy from 20 analysts. The stock currently trades around 33% below the average share price target, indicating that the stock is likely undervalued at this time.

miggy99 Posted - 23 hours ago

$AZN https://uk.yahoo.com/finance/news/analysts-saying-astrazeneca-share-price-101015404.html

CharlesEscobar Posted - 23 hours ago

$AZN Looking for $55 entry. This stock is trash at these prices.

romanaround Posted - 1 day ago

$VKTX Merck definitely going after $ALT in bidding war $LLY $PFE $AZN

PrinceAli7 Posted - 1 day ago

$AZN This stock is gonna do amazing tomorrow I think

PrinceAli7 Posted - 1 day ago

$AZN Tomorrow will be a good day!

Quantumup Posted - 1 day ago

BTIG🏁 $RNAC Buy; $42, says Cartesian is pioneering the field of mRNA-based CART cell therapies for autoimmune disorders: $argx $azn $kytx $caba BTIG Re: Cartesian’s lead mRNA cell therapy candidate and a potential first-in-class mRNA CAR-T, Descartes-08: $RNAC's (Cartesian's) lead efforts are in myasthenia gravis (MG), which has provided important proof of concept for Descartes-08 with differentiated efficacy that looks progressive through long-term follow-up. This also represents a significant market opportunity (>120k patients in US and EU; Vyvgart is at over a $2B run-rate 11 quarters into launch) despite existing Tx options, where we expect Descartes-08's unparalleled efficacy and unusually clean safety to be well received:

BentleyT99 Posted - 1 day ago

$INO $CHRS $INCY $AZN

Fingerlickengood Posted - 1 day ago

$INO $CHRS $INCY $AZN This is only the 1st of many more life saving and 'cost-effective' cancer treatments to come using Loqtorzi (aka: toripalimab)! What more proof does one need? https://pmc.ncbi.nlm.nih.gov/articles/PMC11097128/

miggy99 Posted - 1 day ago

$AZN added 50S @ 64.40 👍

Fingerlickengood Posted - 1 day ago

$CHRS $AZN $INCY $INO

PFElinepfrenzy1990 Posted - 1 day ago

$PFE $BMY $AZN $LLY - Well, I suppose healthcare bad AI good 🙄 who needs healthcare when we have Blackwell chips and self-driving cars and quantum computing?

CharlesEscobar Posted - 1 day ago

$AZN Probably going to lose all of China, their second biggest market. This trash is headed much lower.

BrodieMcCl Posted - 1 day ago

$AZN 🔥 MYNZ 🚨 +48% - Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test DGX to distribute NextGen nationwide (18-mo option), $8M to fast-track FDA, TMO co-developing mRNA-based CRC screening. Supporters: P. Starke, G. Starke, F. Muniz. Low float, $50 soon! 🔥

ThisIsBiotech Posted - 1 day ago

$CHRS $AZN $MRK $JNJ $INCY The global liver cancer drugs market is expected to expand by $3.28 billion from 2024 to 2028, driven by the rising incidence of liver cancer and advancements in targeted and immunotherapies, according to a Technavio report. The increasing prevalence of chronic conditions such as hepatitis, alcohol-related liver disease, and nonalcoholic fatty liver disease (NAFLD) is boosting demand for innovative treatments. Key developments in personalized therapies, including immune checkpoint inhibitors and monoclonal antibodies, are improving survival rates and enhancing patient outcomes. Emerging markets, particularly in Asia-Pacific, represent significant opportunities due to high disease prevalence. With a growing therapeutic pipeline and expanding access to cutting-edge treatments, the market is set to witness rapid advancements, offering hope for improved care and better quality of life for liver cancer patients globally. https://www.prnewswire.com/news-releases/liver-cancer-drugs-market-size-is-set-to-grow-by-usd-3-28-billion-from-2024-2028--increasing-incidence-of-liver-cancer-to-boost-the-market-growth-technavio-302214534.html

CharlesEscobar Posted - 1 day ago

$AZN I like this at $55

Thestocktraderhubzee Posted - 2 days ago

WATCHLIST DEC 19 2024. $GSK CA Governor Newsom Proclaimed State Of Emergency To Further Enhance State's Preparedness And Accelerate The Bird Flu Cross-Agency Response Efforts $AMST Amesite shares are trading higher after the company disclosed its healthcare app Nursemagic won contracts with hundreds of high-growth companies across the country. $CRBG Piper Sandler Maintains Overweight on Corebridge Financial, Raises Price Target to $35 $REAX BTIG Initiates Coverage On Real Brokerage with Buy Rating, Announces Price Target of $6 $AZN Alexion, AstraZeneca Rare Disease Announces Agreement With Pan-Canadian Pharmaceutical Alliance For Koselugo In Treatment Of Paediatric Patients With Neurofibromatosis Type 1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

SparkySC Posted - 2 days ago

$SPY $QQQ $MRNA $AZN $MRK Russia has developed an mRNA vaccine against cancer, Russian news agency TASS has reported. The vaccine will be distributed to cancer patients for free, General Director of the Radiology Medical Research Center of the Russian Ministry of Health, Andrey Kaprin, told Radio Rossiya. The vaccine has been developed in collaboration with several research centers and is expected to be released for public use by early 2025.

PrinceAli7 Posted - 2 days ago

$AZN It’s no coincidence that a UK-based giant like AstraZeneca is under China’s microscope. Despite this distraction, AZN’s fundamentals and leadership in global healthcare innovation shine through.

PrinceAli7 Posted - 2 days ago

$AZN AstraZeneca’s parallel licensing strategy shows regulatory confidence across regions. With approvals in the U.S., EU, and Asia likely for key oncology drugs, the stock has strong upside potential.

PrinceAli7 Posted - 2 days ago

$AZN is making significant strides in the rare disease market with Alexion’s latest advancements. The recent FDA approval and expanding pipeline highlight the company’s strong position in this high-growth sector. With continued momentum and a robust portfolio of innovative treatments, AstraZeneca is primed for substantial long-term growth. This is a stock to watch as they continue to lead in rare disease therapies.

CharlesEscobar Posted - 2 days ago

$AZN Lol where's that technical guy who blocked me? I thought this was going to $80 😄

EmbraceVolatility Posted - 2 days ago

$AZN Bunch of numskulls on this board. $64 is the floor. Possibly touch that Friday due to 3xW. I will give them that.

CharlesEscobar Posted - 2 days ago

$AZN I think $55 is fair value. My puts are printing $$